• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • About
  • Our Products
    • Restoret
  • Team
EyeBio

EyeBio

  • Business Development
  • News
  • Contact

Back to Team

Andreas Wallnoefer, Ph.D.

Partner & Investor, Jeito Capital

LinkedIn

Andreas is a Partner and Investor at Jeito Capital. He has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma (Roche) R&D Executive Leadership team, and five years as General Partner in the European venture capital firm, BioMedPartners.

As an investor, Andreas has successfully developed innovative companies and has been a board member of several European biotech companies. Prior to his career in venture capital, he was Head of Cardiovascular and Metabolism (CVM) R&D at Roche and a member of the Roche/Genentech Portfolio Committee. Andreas was part of several successful product developments and market introductions. Before the integration of Genentech (now a wholly owned member of The Roche Group), Andreas was Global Head of Clinical Research and Exploratory Development and led the R&D organization at multiple sites in Europe, the U.S., and Asia. He had a key role in the integration of the Roche and Genentech development organizations and subsequently led Roche’s Early Development Department.

Andreas holds a Ph.D. in Pharmacology from the University of Basel, degrees in Pharmaceutical Medicine, and was trained as a Clinical Research fellow at the Centre of Human Drug Research at the University Hospital of Leiden, Netherlands. He also holds an Executive M.B.A. from IMD Lausanne.

Footer

Contact Us

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

Business Development

EyeBio is bringing disruptive innovation to the field of ophthalmology. We actively seek to expand our pipeline of promising investigational therapies, and we welcome inquiries regarding in-licensing and acquisition of assets into our portfolio.

To learn more, please contact Sarah Milsom, Chief Operating Officer of EyeBio, at s.milsom@nulleyebiotech.com.

Privacy Policy
Terms of Use
Cookie Policy
Accessibility Statement

EyeBio

LinkedIn

Copyright © 2022 EyeBio

logo
  • About
  • Our Products
    • Restoret
  • Team
  • Business Development
  • News
  • Contact